Novosibirsk · Russian-qualified counsel Recognised by Pravo-300 · Best Lawyers · Kommersant
Tax

What are the main procedural steps in Article 54.1 unjustified tax benefit doctrine in Russia in the pharmaceuticals sector?

Kristina Kornouhova · January 2026 · 3 min read

FTS applies Article 54.1 unjustified tax benefit rules with particular force in Russian pharma. What in-house counsel needs to know. Make an enquiry.

Under Russian tax law, Article 54.1 of the Tax Code – the unjustified tax benefit doctrine – empowers the Federal Tax Service to deny deductions and VAT credits where a transaction lacks genuine economic substance or where the counterparty named in the contract did not actually perform the obligation. In the pharmaceuticals sector, the FTS has applied this doctrine with particular consistency in recent audit cycles, targeting supply chain arrangements where nominal intermediaries sit between a foreign-owned entity and end distributors, and where documentary evidence linking physical goods to the contracting parties is incomplete.

The enforcement sequence under Russian law proceeds in defined stages. The FTS typically opens a field audit (выездная проверка) or, for individual transactions, a desk audit (камеральная проверка). At the close of the audit, the FTS issues a formal audit act setting out the alleged violations. The taxpayer has the right to file written objections within one month. The FTS then issues a decision – upholding, modifying, or dismissing the initial findings. An adverse decision must be appealed internally to the regional FTS directorate before any court challenge is admissible; this pre-trial administrative stage is mandatory under Russian tax procedure. If the internal appeal does not resolve the dispute, the taxpayer may bring proceedings before the relevant arbitrazh court.

For pharmaceutical companies specifically, the FTS examination focuses on three areas: the commercial rationale for using intermediary distributors; the documentary chain confirming that the counterparty named in the contract performed the supply; and the correspondence between declared purchase prices and market-level benchmarks. Transfer-pricing-adjacent scrutiny is common even where a formal transfer-pricing audit has not been opened. Circuit courts across the Siberian and Ural federal districts have handled a material volume of pharma-sector Article 54.1 disputes, and the outcome often turns on the quality of the primary documentation rather than the economic substance analysis alone.

In-house counsel at pharmaceutical companies with Russian subsidiaries should initiate a documentation review before a field audit notice arrives. The window between audit commencement and the first FTS information request is narrow, and remediation of documentary gaps after that point is procedurally constrained.

For a broader analysis of the doctrine and the three statutory conditions a taxpayer must satisfy, see Article 54.1 unjustified tax benefit doctrine in Russia and A practical guide to Article 54.1 unjustified tax benefit. The firm's Tax Controversy practice page sets out how Vetrov & Partners advises at each stage of the FTS audit and appeal cycle.

Make an enquiry — info@vetrovpartners.com |

— Kristina Kornouhova Senior Lawyer, Practice Lead — Tax & Antitrust, Vetrov & Partners vetrovpartners.com/kornouhova/

Kristina Kornouhova heads the firm's tax controversy and antitrust practices. She advises Russian and foreign companies facing Federal Tax Service audits, transfer-pricing disputes, and FAS Russia proceedings. Her work spans pre-litigation tax structuring, voluntary disclosure coordination, and market-definition analyses in antitrust investigations.

Practitioner note

This briefing is general information and does not constitute legal advice. For advice on a specific matter, write in confidence to info@vetrovpartners.com.

Facing a matter like this?

Our team advises foreign clients on exactly these questions across Russia and the EAEU region. Initial 30-minute consultation — complimentary.

Make an enquiry